The FDA has issued warning letters to five more U.S.-based peptide sellers, the agency's latest move in an ongoing enforcement push against companies marketing unapproved versions of popular GLP-1 drugs and other injectable peptides under "research use only" labels. The letters, dated August 24, 2026 and made public on the FDA's website on September 1, 2026, went to Peak Performance Peptides (Arizona), Royal Peptides LLC and Peptide Partners LLC (both Florida), NuScience Peptides LLC (North Carolina), and TXP Innovations LLC, doing business as Tex Peptides (Texas).

What the Letters Say

Across the five letters, the FDA identified sales of semaglutide, tirzepatide, retatrutide, survodutide, mazdutide, the mitochondrial peptide SS-31, the sexual-dysfunction peptide PT-141, and the growth-hormone-adjacent compound tesamorelin, along with bacteriostatic water commonly sold alongside them for reconstitution. According to the agency, the deciding factor wasn't the "research use only" disclaimer on each product's label, but how the companies actually marketed it: website claims describing weight loss, blood sugar control, sexual function, body composition, and broader metabolic health effects, in the FDA's view, established that these products were intended for human use as drugs. That intended-use standard is the same one the FDA has applied in prior sweeps against peptide sellers, discussed elsewhere on this site.

The FDA's letters cite violations of sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act, covering the introduction of an unapproved new drug into interstate commerce. None of the cited products have an FDA-approved application covering the versions these companies sold, regardless of whether the same active ingredient (like semaglutide or tirzepatide) is FDA-approved in a different, properly regulated branded or generic form. Each company was given 15 business days to describe the specific corrective actions it would take.

Regulatory Status of the Peptides Involved

It's worth separating the compounds by their actual approval status. Semaglutide and tirzepatide are FDA-approved, but only as the specific branded products Ozempic, Wegovy, Mounjaro, and Zepbound, manufactured under approved applications with their own quality controls; a vial sold by an unrelated peptide seller is not the same regulated product even if it contains the same molecule. Retatrutide, survodutide, and mazdutide remain investigational, with no FDA approval for any use. PT-141 (bremelanotide) is FDA-approved as the branded drug Vyleesi for one specific indication in women; sold as an unbranded injectable for general sexual-dysfunction use, it falls outside that approval. Tesamorelin is FDA-approved as Egrifta for a specific indication related to HIV-associated lipodystrophy, not as a general-purpose peptide product.

Why This Keeps Happening

This sweep brings the number of FDA warning-letter actions against peptide sellers documented on this site into the double digits over the past year, reflecting a sustained enforcement focus on the research-chemical-labeled peptide market rather than a single one-off action. The agency has signaled, including in the peptide compounding advisory panel process covered elsewhere on this site, that it is trying to draw a clearer line between legitimate research supply and consumer-facing drug sales dressed up with a research disclaimer.

What This Means for Consumers

A warning letter is not a product recall and doesn't automatically pull anything off a website. It's a formal notice that the FDA considers a company's conduct illegal and a first step that can lead to seizure, injunction, or referral for further action if the company doesn't correct course. For anyone considering a peptide purchased this way, the practical risk is the same one discussed throughout this site's safety coverage: no FDA oversight of manufacturing, purity, or labeling accuracy, and no guarantee the product matches what the label claims. Anyone currently using a product named in an FDA warning letter, or considering starting one, should talk to a licensed physician about safer, properly regulated alternatives for whatever condition they're trying to address.